Bortezomib plus dexamethasone for rituximab-resistant PLA2R+ membranous nephropathy
- 1 September 2021
- journal article
- letter
- Published by Elsevier BV in Kidney International
- Vol. 100 (3), 708-709
- https://doi.org/10.1016/j.kint.2021.04.011
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Rituximab in Membranous NephropathyKidney International Reports, 2021
- Obinutuzumab is Effective for the Treatment of Refractory Membranous NephropathyKidney International Reports, 2020
- Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathyNephrology Dialysis Transplantation, 2019
- Treatment of membranous nephropathy: time for a paradigm shiftNature Reviews Nephrology, 2017